Live Breaking News & Updates on Relapsed or refractory acute myeloid leukemia

Stay updated with breaking news from Relapsed or refractory acute myeloid leukemia. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

FDA Grants Fast Track Designation to Tamibarotene/Azacitidine/Venetoclax for RARA-Overexpressed AML

Tamibarotene plus azacitidine and venetoclax has received FDA fast track designation for newly diagnosed, unfit, RARA-overexpressed AML. ....

Davida-roth , Syros-pharmaceuticals , Fda , Aml , Relapsed-or-refractory-acute-myeloid-leukemia , Nct04588922 , Arara , Fast-track-designation ,

FDA Grants Fast Track Status to SLS009 for Relapsed/Refractory Acute Myeloid Leukemia

The FDA has granted fast track designation to SLS009 for use as a potential therapeutic option in patients with relapsed or refractory acute myeloid leukemia. ....

Angelos-stergiou , Life-sciences-group-inc , Life-sciences , Sciences-group , Fda , Sls009 , Aml , Relapsed-or-refractory-acute-myeloid-leukemia , Nct04588922 ,

Bexmarilimab Plus SOC Continues to Elicit Responses in R/R AML and HMA-Refractory MDS

The addition of bexmarilimab to standard-of-care azacitidine or azacitidine plus venetoclax continued to elicit responses in patients with relapsed or refractory acute myeloid leukemia and those with myelodysplastic syndrome who were refractory to hypomethylating agents. ....

United-states , Markku-jalkanen , Faron-pharmaceuticals , Faron-pharmaceuticals-ltd , International-prognostic-scoring-system , Bayesian-optimal-interval , Bexmarilimab , Rr-aml , Relapsed-or-refractory-acute-myeloid-leukemia , Hypomethylating-agents , Phase-1-2-bexmab-study-nct05428969- , Azacitidine